Another study has further established that FOXO3 activation increases expression of TRAIL and cell death in response to doxorubicin in hepatocellular carcinoma (HCC), suggesting that FOXO3 is required for doxorubicin-sensitivity. The gene discussed is TNFSF10; the disease is hepatocellular carcinoma.